Annual Research Report Tabula Rasa Healthcare: Calendar Year 2019
Total Page:16
File Type:pdf, Size:1020Kb
2020 Annual Research Report Tabula Rasa HealthCare: Calendar Year 2019 Copyright © 2020, Tabula Rasa HealthCare, Inc., all rights reserved. These materials are confidential and proprietary information of Tabula Rasa HealthCare, Inc. and may not be reproduced in whole or in part without the written consent of Tabula Rasa HealthCare, Inc. Table of contents Research Strategy Committee 6 Research dissemination 10 Peer-reviewed published articles 12 Published abstracts and posters at scientific meetings 14 Published newsletters 16 Live presentations 18 Publications In press 19 Professional awards and recognition 20 Professional leadership roles 21 Peer reviewers for journals 22 Postgraduate residency programs 23 Current research projects 26 Applied Precision Pharmacotherapy Institute SinfoníaRx corporate office Precision Pharmacotherapy Research & Development Institute Annual report from the Tabula Rasa HealthCare, Inc. research pillar The Tabula Rasa HealthCare (TRHC) Research & Development Pillar is committed to the development and dissemination of population health and patient-specific, data-driven technology and solutions that optimize medication regimens, manage medication risks, improve patient outcomes, reduce hospitalizations, and decrease healthcare costs. Last year was transformational for the TRHC Research & Development Pillar, as it marked the unification of numerous nationwide research collaborators, including partners from the Precision Pharmacotherapy Research & Development Institute, Applied Precision Pharmacotherapy Institute, TRHC's Healthcare Analytics department, DoseMe, SinfoníaRx, The University of Arizona College of Pharmacy, and The Ohio State University Institute of Therapeutic Innovations and Outcomes. In 2019, our mission to disseminate outcomes specific to TRHC solutions led to an impressive volume of publications. Our researchers published 26 papers in renowned journals, including the British Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, The Journal of the American Osteopathic Association, Epilepsy Research, Journal of the American Pharmacists Association, and Xenobiotica. Research and Development Pillar members were cited 187 times last year in the areas of pharmacogenomics, drug-drug interactions, medication therapy management, transitions of care, and cytochrome P450 activity. Our national team gained stakeholder knowledge as they served in more than 45 leadership roles in professional organizations. Our team also contributed to the research community by actively participating as peer reviewers for more than 20 leading journals, producing 37 abstracts and poster exhibits, and leading 34 live scholarly presentations. Congratulations to our valued members of the TRHC Research & Development Pillar who received more than 36 professional awards last year! As we look forward, we are excited to strengthen our reputation in the healthcare industry as a leading provider of high-quality research, with 9 papers already in-press with prominent journals. Dr. Jacques Turgeon Chief Scientific Officer Tabula Rasa HealthCare Research Strategy Committee The TRHC Research Strategy Committee is composed of members from the Applied Precision Pharmacotherapy Institute, SinfoníaRx, Precision Pharmacotherapy Research and Development Institute, The Ohio State University Institute of Therapeutic Innovations and Outcomes, and The University of Arizona. The committee meets monthly to advocate for research dissemination and to support TRHC's mission and vision. Page 6 Jenny Bingham, PharmD, BCACP, is President of the TRHC Research Strategy Committee. She promotes the excellence and growth of TRHC through oversight of research from project conceptualization to outcomes dissemination. Dr. Bingham is passionate about advancing the role of pharmacists in the telehealth setting and was recognized as the Next-Generation Pharmacist® Technology Innovator of the Year for her efforts in successfully leveraging telehealth pharmacy models to advance patient care standards and business profitability. Sandra Leal, PharmD, MPH, FAPhA, CDE, is Executive Vice President of the TRHC Health Plans and Payers Business Unit. Dr. Leal is responsible for oversight and forward-thinking expansion of pharmacists’ services that focus on outcomes, access, and quality. Dr. Leal was recognized as the American Pharmacists Association Good Government Pharmacist-of-the-Year for her advocacy work on pharmacist provider status and is the president-elect of the American Pharmacists Association for the 2020-2021 term. Veronique Michaud, PhD, BPharm, is Chief Operating Officer of the TRHC Precision Pharmacotherapy Research & Development Institute in Orlando, Florida. She is an adjunct professor, Faculty of Pharmacy, at the University of Montreal and has directed a pharmacokinetic and bioanalytic core facility at the University of Montreal Hospital Research Centre. Her research investigates the contribution of cyptochrome 450 drug- metabolizing enzymes in drug disposition, with special attention on the role of disease states, focusing on type 2 diabetes mellitus. She has earned more than $22 million in research awards, published more than 40 peer-reviewed journal articles, and mentored graduate students and PharmD residents. Dr. Michaud completed fellowships at Indiana University in Indianapolis and McGill University in Montreal and earned Doctoral and Master of Science degrees at the University of Montreal in Canada. Page 7 Research Strategy Committee (Continued) Milap C. Nahata, PharmD, MS, is Founding Director of the Institute of Therapeutic Innovations and Outcomes at The Ohio State University College of Pharmacy. He has published more than 600 peer-reviewed journal articles, book chapters, and five books about the clinical pharmacokinetics, pharmacodynamics, effectiveness, and safety of medications used in adult and pediatric patients. Additional research interests include impact of the population’s social determinants on their health outcomes with the usage of medications. Luke Oglesby, BS, is a SinfoníaRx Business Systems Analyst. He received a Bachelor of Science in Biology with a minor in Health Care Management from Metropolitan State University of Denver in Colorado. Luke is responsible for ensuring that SinfoníaRx can provide the most valuable data possible for client outcome reports. Jeniece Roher, CIPP/US, CIPP/G, MCM, is Chief Compliance Officer, HIPAA Privacy Officer at TRHC. She provides multifaceted leadership for the organizational compliance program and serves as the individual responsible for establishing and implementing an effective compliance program to prevent illegal, unethical, or improper conduct. Vanessa Ruiz, BS, is Project Manager & Operations Coordinator at The University of Arizona College of Pharmacy Research Team. Vanessa has more than three years of experience in project and relationship management and strategic planning in research and business, including as an external affairs associate to improve policies for high- performing, low-income Arizona K-12 schools. Since joining the research team, she has been instrumental in expanding and improving day-to-day operations; elevating the team’s overall efficiency and effectiveness; and collaborating with partner organizations on the communication, design, and dissemination of innovative research. Page 8 Nicole Scovis, PharmD, BCPS, BCACP, is Director of Strategic Growth at TRHC, where she pilots new pharmacy services in areas such as integrated behavioral health clinics, accountable care organizations, and private wellness programs. Program implementation focuses on improvement in clinical, economic, and humanistic outcomes, and ultimately on sustainability and scalability to allow broader access to these services. Dr. Scovis also helps to develop and maintain clinical programs across the SinfoníaRx line of business and serves as a faculty member at The University of Arizona College of Pharmacy. Ann M. Taylor, MPH, MCHES, is Editor and Director of Operations for The University of Arizona College of Pharmacy Research Team and plays a key role in compliance and editorial review, as well as in ensuring rapid dissemination of research results for the research team and partnering organizations. Her extensive research career has involved coordinating Phase I-III clinical studies for refractory cancers, large-scale federal grants, and contracts with national and state entities. She has collaborated with interprofessional teams on the development and evaluation of innovative programs for diverse audiences. Ann is a Master Certified Health Education Specialist (MCHES) who has authored more than 30 peer-reviewed publications on cancer prevention, medication therapy management, and end-of-life care, and she has presented at regional and national conferences. Jacques Turgeon, PhD, BPharm, Chief Scientific Officer of TRHC and is recognized internationally for his excellence in research and pharmacy education. He has received more than $70 million in research awards, authored more than 145 peer-reviewed articles, and mentored nearly 70 students. His research interests focus on studying factors responsible for the intersubject variability in drug response, and he is renowned for his expertise in the role of pharmacogenetics in cardiovascular drug actions. Dr. Turgeon is also professor emeritus at the University of Montreal, fellow of the Canadian Academy of Health Sciences, and fellow of the Académie Nationale de Médecine, France. Terri Warholak, PhD, RPh, FAPhA, CPHQ,